Journal: Cell Reports Medicine

Article Title: IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

doi: 10.1016/j.xcrm.2024.101567

Figure Lengend Snippet:

Article Snippet: Anti-mouse/human TCF1 AF488 (clone: C63D9) , Cell Signaling , Cat# 6444S; RRID: AB_2797627.

Techniques: Purification, Recombinant, Formulation, Flow Cytometry, Amplification, Software, Staining

Journal: Immunity

Article Title: TCR-independent CD137 (4–1BB) signaling promotes CD8 + -exhausted T cell proliferation and terminal differentiation

doi: 10.1016/j.immuni.2023.06.007

Figure Lengend Snippet: (A–D) Naive WT mice were treated with anti-CD137 (3H3, 10 μg) or IgG control mAbs. (A) Experimental design. (B–D) FACS plot and graphs showing Ki-67 expression by the indicated CD8 + T cell subsets along treatment. (E and F) The indicated CD45.1 CD8 + T cell subsets were injected i.v. into Cd137 −/− mice that were treated with anti-CD137 or IgG. (E) Experimental design. (F) FACS plot and graphs showing the frequency of CD45.1 + CD8 + T cells after 14 days. (G–K) WT mice were injected with anti-CD137 or IgG. The indicated splenic CD8 + T cell subsets were analyzed by scRNA-seq (n = 5–10 pooled mice/group). (G) Experimental design. (H and I) UMAP (H) and bar plots (I) showing CD8 + T cell cluster distribution. (J) Relative expression of Tnfrsf9 . (K) Clustered heatmap showing the indicated signature expression (1: Miller et al. ; 2: Siddiqui et al. ; 3: Utzschneider et al. ; 4: Giles et al. ). Data are scaled rowwise. (L) Clustered heatmap showing the 280 differentially expressed genes between Tex-like cells treated with anti-CD137 or Ig (log 2 FC > 0.25). (M–P) The indicated CD8 + T cell subsets isolated from WT mice treated with anti-CD137 were injected i.v. into Rag2 −/− Il2rg −/− mice treated with anti-CD137 or IgG. (M) Experimental design. (N) FACS plots and numbers of CD8 + T cells recovered after 7 days. (O) FACS plots and graphs showing PD1 and Tim3 expression and numbers. (P) Frequency of CD8 + T cells with a Tmem (CD44 hi PD1 − ), Tpex (PD1 + TCF1 + Tim3 − ), or TermTex (PD1 + TCF1 − Tim3 + ) cell phenotype. Data are presented as mean ± SEM from at least 2 independent experiments. Each symbol represents an individual mouse. *p < 0.05; **p < 0.01, ***p < 0.001 (paired t test or ANOVA with Tukey’s post-test analysis).

Article Snippet: Anti-human/mouse Tcf1/tcf7 AF488 [C63D9] , Cell Signaling Technology , Cat#: 6444S.

Techniques: Expressing, Injection, Isolation

Journal: Immunity

Article Title: TCR-independent CD137 (4–1BB) signaling promotes CD8 + -exhausted T cell proliferation and terminal differentiation

doi: 10.1016/j.immuni.2023.06.007

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Anti-human/mouse Tcf1/tcf7 AF488 [C63D9] , Cell Signaling Technology , Cat#: 6444S.

Techniques: Purification, Recombinant, Lysis, Negative Control, Cell Isolation, Staining, Knock-Out, Isolation, Infection, RNA Sequencing Assay, Software, Expressing

Journal: Cell Host & Microbe

Article Title: Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox

doi: 10.1016/j.chom.2023.04.015

Figure Lengend Snippet: Phenotypical profile of VACV/MPXV tetramer + CD8 + T cells in HBDs and mpox patients (A) Representative flow plots showing VACV/MPXV tetramer staining on CD8 + T cells (left) and frequencies (right). (B) Frequencies of naive and memory T cell subsets within tetramer + CD8 + T cells in HBDs and convalescent donors. (C) UMAP visualization of tetramer + CD8 + T cells from HBDs and convalescent donors, and expression of individual markers colored by marker expression levels. (D) Frequency of HLA-DR + CD38 + , Ki-67 + , Granzyme B + CD8 + T cells, and CXCR3 + expression in HBDs vs. convalescent donors. (E) Representative flow plots of transcription factors expression within VACV/MPXV + CD8 + T cells in HBDs vs. convalescent donors (left) and quantification (right). (F) Frequency of T-bet + CX3CR1 + terminally differentiated (effector) cells in HBDs vs. convalescent donors. (G) Spearman correlation of marker expression with time after symptom onset. (H and I) Frequency of MPXV-specific T SCM cells identified with tetramers (H) or AIM assay (I) after mild vs. moderate mpox. (J) Frequency of TCF1 + cells and TCF1/T-bet ratio among tetramer + cells after mild vs. moderate mpox. In (A), (B), (D)–(F), and (H)–(J), Mann-Whitney test. In (G), Spearman rank correlation. See also Figure S4 .

Article Snippet: Anti-human TCF1 AF488 , CellSignaling , Cat# 6444S; RRID: AB_2199302.

Techniques: Staining, Expressing, Marker, MANN-WHITNEY

Journal: Cell Host & Microbe

Article Title: Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox

doi: 10.1016/j.chom.2023.04.015

Figure Lengend Snippet:

Article Snippet: Anti-human TCF1 AF488 , CellSignaling , Cat# 6444S; RRID: AB_2199302.

Techniques: Recombinant, Staining, Software

Journal: Immunity

Article Title: In situ maturation and tissue adaptation of type 2 innate lymphoid cell progenitors

doi: 10.1016/j.immuni.2020.09.002

Figure Lengend Snippet:

Article Snippet: Anti-mouse/human TCF1/7 AF488 (Clone C63D9) , Cell Signalling , Cat # 6444S.

Techniques: Mouse Assay, Software